Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Lethal congenital contracture syndrome type 1 is a rare, genetic arthrogryposis syndrome characterized by total fetal akinesia (detectable since the 13th week of gestation) accompanied by hydrops, micrognathia, pulmonary hypoplasia, pterygia and multiple joint contractures (usually flexion contractures in the elbows and extension in the knees), leading invariably to death before the 32nd week of gestation. Lack of anterior horn motoneurons, severe atrophy of the ventral spinal cord and severe skeletal muscle hypoplasia are characteristic neuropathological findings, with no evidence of other organ structural anomalies.
Features include very common findings: Hypertelorism, Abnormal hip bone morphology, and Short stature; and common findings: Posteriorly rotated ears, Webbed neck, Short neck, and Abnormal rib morphology and others. 25 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 7 | Skeletal muscle atrophy, Limitation of joint mobility, Recurrent fractures |
GLE1 encodes GLE1 RNA export mediator (698 aa). Required for the export of mRNAs containing poly(A) tails from the nucleus into the cytoplasm. May be involved in the terminal step of the mRNA transport through the nuclear pore complex (NPC) Highest expression in Testis (66.4 TPM) and Cells EBV-transformed lymphocytes (52.3 TPM).
Lethal congenital contracture syndrome 1 is associated with mutations in the GLE1 gene on chromosome 9.
GLE1 is classified as a druggable target (Transporter category) with score 26.1.
Genetic testing for GLE1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for lethal congenital contracture syndrome 1 has been reported in the published literature.
Phenotype severity distribution: 3 very common features, 11 common features.
No clinical trials have been registered for lethal congenital contracture syndrome 1.
2 publications have been identified in PubMed for lethal congenital contracture syndrome 1. Research spans Diagnostic / Biomarker (50%) and Basic Science / Preclinical (50%).
Zárybnický T (2025). [PMID: 40674274](https://pubmed.ncbi.nlm.nih.gov/40674274/). *The FEBS journal*. [Basic Science / Preclinical]
Rajala K (2025). [PMID: 39674903](https://pubmed.ncbi.nlm.nih.gov/39674903/). *Prenatal diagnosis*. [Diagnostic / Biomarker]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 11:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Muscles |
3 |
Skeletal muscle atrophy, Joint stiffness present at birth (arthrogryposis multiplex congenita), Limitation of joint mobility |
Lungs and breathing | 1 | Pulmonary hypoplasia |
Growth and development | 1 | Short stature |